Pancreatic cancer is one of the most aggressive malignancies. In order to change its devastating prognosis, a novel therapeutic approach must be developed. The conditionally replicative adenovirus (CRAd) is one such promising therapeutic modality for pancreatic cancer. CRAd clinical trials to date have established the safety of these agents and identified their current limitations, and our laboratory is developing safer and more potent CRAds for therapeutic use. In this proposal, we plan to develop of a new generation pancreatic cancer CRAds with superior therapeutic potency and disease selectivity by exploiting the specific molecular features of this disease itself. We have developed new generation vector modifications which can provide a different level of transduction efficiency, and recent advancements in pancreatic cancer molecular biology have identified several target-worthy molecular features. The CRAds engineered for better potency and target specificity will be outfitted with anti-tumor effectors modifying pancreatic cancer tumor environment. New vectors will be tested not only with mouse subcutaneous and orthotopic xenograft models but also with models showing close relevance to human clinical situations. A hamster syngeneic pancreatic cancer model which allows human adenoviral replication will provide deeper insight into CRAd biology. The CRAd function analysis based on tissue slice technology permits us to evaluate CRAds in patient materials. These assessments will be further strengthened by the non-invasive viral replication monitoring capability we have developed. The development and analysis of next-generation CRAds will precede a clinically meaningful and novel therapy for pancreatic cancer.

Public Health Relevance

The poor prognosis for pancreatic cancer drives our effort to develop new therapeutic modalities. More potent and safer CRAds can be fashioned into a clinically effective therapeutics. Also, detailed analyses of CRAd functionality in clinically relevant models will provide the crucial information required to advance vector design. The outcome of this project will lead to a clinically usable therapeutics for pancreatic cancer.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Project (R01)
Project #
Application #
Study Section
Developmental Therapeutics Study Section (DT)
Program Officer
Arya, Suresh
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Minnesota Twin Cities
Schools of Medicine
United States
Zip Code
Yamamoto, Yuki; Goto, Naoko; Miura, Kazuki et al. (2014) Development of a novel efficient method to construct an adenovirus library displaying random peptides on the fiber knob. Mol Pharm 11:1069-74
Oneal, M J; Trujillo, M A; Davydova, J et al. (2013) Effect of increased viral replication and infectivity enhancement on radioiodide uptake and oncolytic activity of adenovirus vectors expressing the sodium iodide symporter. Cancer Gene Ther 20:195-200
Miura, Yoshiaki; Yamasaki, Satoshi; Davydova, Julia et al. (2013) Infectivity-selective oncolytic adenovirus developed by high-throughput screening of adenovirus-formatted library. Mol Ther 21:139-48
Pham, Lan; Beyer, Kayla; Jensen, Eric D et al. (2011) Bone morphogenetic protein 2 signaling in osteoclasts is negatively regulated by the BMP antagonist, twisted gastrulation. J Cell Biochem 112:793-803
Yamamoto, Masato; Curiel, David T (2010) Current issues and future directions of oncolytic adenoviruses. Mol Ther 18:243-50
Short, Joshua J; Rivera, Angel A; Wu, Hongju et al. (2010) Substitution of adenovirus serotype 3 hexon onto a serotype 5 oncolytic adenovirus reduces factor X binding, decreases liver tropism, and improves antitumor efficacy. Mol Cancer Ther 9:2536-44
Yamasaki, Satoshi; Miura, Yoshiaki; Brown, Eric et al. (2010) Development of a method for effective amplification of human adenovirus 40. Arch Virol 155:1059-68
Arrington, Amanda K; Davydova, Julia; Vickers, Selwyn M et al. (2009) Anti-ERBB2 sh-RNA suppress both cell growth and tumor growth in ERBB2-overexpressing upper gastrointestinal adenocarcinomas. J Gastrointest Surg 13:1754-61
Nelson, Amy R; Davydova, Julia; Curiel, David T et al. (2009) Combination of conditionally replicative adenovirus and standard chemotherapies shows synergistic antitumor effect in pancreatic cancer. Cancer Sci 100:2181-7
Ramirez, Pedro J; Vickers, Selwyn M; Ono, Hidetaka A et al. (2008) Optimization of conditionally replicative adenovirus for pancreatic cancer and its evaluation in an orthotopic murine xenograft model. Am J Surg 195:481-90

Showing the most recent 10 out of 52 publications